(2S)-2-{[(2R)-1-{[(4S,7R,10S,13R,16S)-13-benzyl-10-(2-carbamoylethyl)-7-(carbamoylmethyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl]carbonyl}pyrrolidin-2-yl]formamido}-N-(carbamoylmethyl)-5-[(diaminomethylidene)amino]pentanamide indication Von Willebrand disease, platelet type (Knowledge Graph Assertion)

Target:

Von Willebrand disease, platelet type

Source:

(2S)-2-{[(2R)-1-{[(4S,7R,10S,13R,16S)-13-benzyl-10-(2-carbamoylethyl)-7-(carbamoylmethyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl]carbonyl}pyrrolidin-2-yl]formamido}-N-(carbamoylmethyl)-5-[(diaminomethylidene)amino]pentanamide

Compound (Entity type)

Relation:

indication

Knowledge Graph Relation (Entity type)

Dcc Asset:

IDG.zip

Processed File (Entity type)

Dcc:

IDG

DCC (Entity type)

Sab:IDGD

Results found

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2025

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.